Peptide Half-Life & Pharmacokinetics: Why Dosing Cadence Varies

Two peptides can hit the same receptor with the same molecular logic and still be dosed on completely different schedules, one every morning, the other once a week. The reason has almost nothing to do with what the peptide does at the cell and almost everything to do with how long it survives in the bloodstream. That is the domain of pharmacokinetics, and its headline number is the half-life.

This is a plain-language guide to peptide pharmacokinetics written for research and educational purposes: what half-life means, how it is measured, the path a peptide takes through the body, and why the answer to "daily or weekly?" is written into the molecule's design. It reports what the published literature describes; it is not medical advice, and the compounds referenced are research compounds not approved for human use. For the receptor side of the story, what these peptides do once they bind, see the companion piece on how peptides work.

Peptide half-life vs dosing interval at a glance

The cleanest way to see the pattern is to line up representative peptides by their approximate half-life next to how often they are dosed. The correlation is the whole point: cadence tracks half-life.

Read the table top to bottom and the logic reveals itself. The peptides at the top are the body's own short-lived signals or their un-engineered analogs; they clear in minutes to hours and must be dosed daily or more often to hold a useful level. The peptides in the middle carry deliberate engineering that stretches their residence time to days, which is what makes once-weekly dosing viable. The half-life column predicts the dosing column, and that is the relationship the rest of this post unpacks. (Figures are approximate and drawn from separate sources; treat them as reported ranges, not exact constants.)

What "half-life" actually means, and how it's measured

A drug's elimination half-life (t½) is the time it takes for its concentration in the blood to fall by half once absorption is complete. If a peptide's plasma level is 100 units now and its half-life is one day, it will be roughly 50 units tomorrow, 25 the day after, and so on. That single number governs almost everything about a dosing schedule, because it sets both how fast a compound washes out and how fast it builds up.

Measuring it is more concrete than it sounds. In a Phase 1 single-ascending-dose study, researchers give one dose to healthy volunteers, then draw blood at timed intervals, a few hours apart at first, then days apart, and measure the peptide's concentration in each sample. Plotting concentration against time produces a curve that typically falls in phases: a fast early drop as the drug distributes into tissues, then a slower final decline as it is genuinely cleared from the body. The terminal half-life is calculated from the slope of that last, slowest phase, the elimination phase, which is why the number is often written as "terminal t½."

One clarification that prevents a common misread: half-life describes how long the peptide lasts, not how strong it is. Potency, how powerfully the molecule activates its receptor, is a separate property. A long half-life means a peptide is present for longer, so exposure accumulates over weeks; it says nothing about the force of each binding event. Two peptides can be equally potent at the receptor and still have half-lives that differ by orders of magnitude.

The ADME path: what the body does to a peptide

Pharmacokinetics is often summarized by four stages a drug moves through, abbreviated ADME: absorption, distribution, metabolism, and excretion. For peptides, each stage has a distinctive twist that separates them from ordinary small-molecule drugs.

Absorption is where peptides announce their difference. A peptide is a chain of amino acids; chemically, it is food, so an oral peptide is attacked by the same digestive enzymes that break down dietary protein, and most of the dose is destroyed before it can be absorbed. ^[7] That is why nearly every therapeutic peptide is injected subcutaneously, into the fat layer under the skin, where it forms a small depot and is absorbed slowly into the blood. That slow absorption pairs with a long half-life to produce the smooth, steady exposure weekly dosing depends on.

Distribution is shaped by size and binding. Peptides are relatively large and water-loving, so they tend to stay in the bloodstream and extracellular fluid rather than diffusing widely into tissues. The engineered long-acting analogs add a twist: by binding to serum albumin, they effectively travel with the body's most abundant blood protein, which keeps them in circulation.

Metabolism is the stage most unlike small-molecule drugs. Where a typical pill is broken down by liver enzymes, a peptide is cleaved by peptidases, enzymes that snip the amino-acid chain. The best-known example is DPP-4 (dipeptidyl peptidase-4), which clips native GLP-1 apart within minutes. ^[5] Making a peptide resist DPP-4 is one of the central tricks of extending its half-life.

Excretion for small peptides runs largely through the kidneys, which filter small molecules out of the blood efficiently. The cleaved fragments are broken down further into amino acids and recycled; a peptide does not leave behind an exotic metabolite the way some small-molecule drugs do, it is ultimately dismantled into the same building blocks the body uses for everything else.

Why some peptides are dosed daily and others weekly

Now the central question. Given that native GLP-1 lasts minutes and semaglutide lasts a week, what closed the gap? Four engineering levers, usually used in combination. Each one slows a different clearance pathway, and stacking them is what turns a minutes-long hormone into a once-weekly drug.

DPP-4 resistance. Native incretins are cut by DPP-4 almost as fast as they are released. Editing the amino acids at the positions DPP-4 attacks makes the peptide invisible to that enzyme, which alone buys a large extension. ^[5] This is the first thing done to nearly every modern GLP-1-class analog.

Molecular size and renal filtration. The kidneys filter small molecules out of the blood quickly; the smaller and more compact a peptide, the faster it is cleared this way. Increasing effective size, including by the albumin trick below, lets a peptide escape the fastest renal filtration, because the kidney does not filter large carrier-bound complexes.

Fatty-acid acylation. Attaching a fatty-acid (lipid) chain to the peptide does two useful things at once: it slows enzymatic breakdown and, crucially, it lets the peptide reversibly bind serum albumin. Semaglutide's roughly 7-day half-life is largely the product of this acylation strategy. ^[8]

Albumin binding. Serum albumin is the most abundant protein in blood and has a very long lifetime of its own. A peptide that clips onto albumin via its fatty-acid tail is effectively hidden inside a large, long-lived carrier, shielded from kidney filtration and slowly released back into free circulation. This is the lever that pushes half-life into the once-weekly range. Retatrutide uses a C20 fatty-diacid linker to do exactly this. ^[2]

The peptides at the short end of the table simply lack these features. Tesamorelin and native GHRH are un-shielded, so peptidases and the kidneys clear them in minutes, and they are dosed daily. BPC-157, a small gastric pentadecapeptide, carries none of the long-acting engineering and has a short (and not well characterized in humans) plasma half-life, which is why research protocols dose it daily or more often. ^[9] The engineering is the difference between a compound you dose every morning and one you dose once a week.

Steady state: why cadence follows half-life

Half-life does not only govern washout; it governs build-up, and that is where dosing cadence comes from. When you dose a long-acting peptide repeatedly, each dose lands before the previous one has fully cleared, so plasma levels climb week over week until the amount going in equals the amount being cleared. That plateau is called steady state, and the rule of thumb is that it arrives after roughly five half-lives. ^[6]

Three practical consequences fall directly out of this, and they apply to any peptide once you know its half-life:

• Early readings understate a long-acting peptide. For the first several weeks, levels are still climbing toward the exposure the dose is designed to deliver. Judging a once-weekly compound at week two is reading the ramp, not the plateau. A short-acting daily peptide, by contrast, reaches steady state in a day or two, so its early effect is much closer to its full effect.
• A missed dose behaves differently depending on half-life. For a weekly, week-long-half-life peptide, one skipped dose lowers exposure but does not return it to baseline, because the compound has accumulated across prior weeks. For a daily, hours-half-life peptide, a missed dose means the drug is essentially gone by the next day; there is no reservoir.
• Washout takes about five half-lives, too. The same math that governs build-up governs clearance. A crossover study or washout period for a 6-day-half-life peptide needs to run several weeks to be real; for a peptide cleared in hours, a day or two suffices.

Why titration cadence follows half-life

The dose-escalation schedules ("titration") used across the GLP-1 class are a direct application of the same pharmacokinetics. The clinical programs for semaglutide, tirzepatide, and retatrutide all raised the dose in steps over weeks rather than starting at the target dose. ^[1] Two half-life facts make that strategy coherent.

First, because a long-acting peptide accumulates, each escalation step layers its exposure onto whatever the previous step had already built. The body is never asked to absorb the full jump from zero to target in one week; it adapts gradually as levels climb. Second, the gastrointestinal effects that dominate the GLP-1 class's tolerability profile are dose- and exposure-dependent, concentrated in the window where levels are changing fastest. Escalating slowly, in step with the ~4 to 5 week approach to steady state at each dose, is the standard lever for keeping those effects manageable. A short-acting peptide that reaches steady state in a day would gain little from this kind of multi-week ramp; the long half-life is precisely what makes stepwise titration both necessary and effective. The retatrutide-specific version of this schedule is covered in retatrutide dosing and titration.

How peptide pharmacokinetics compare to small-molecule drugs

It helps to place peptides against the drugs most people are more familiar with. A typical oral small-molecule drug is swallowed, absorbed through the gut, and metabolized by the liver's cytochrome-P450 enzyme system, the same machinery responsible for most drug-drug interactions. Peptides sidestep almost all of that. They are usually injected rather than swallowed, cleaved by peptidases rather than liver enzymes, and cleared by the kidneys rather than hepatic metabolism. ^[7]

That different route has real consequences. Peptides tend to have fewer classical drug-drug interactions through the liver, because they do not compete for the same P450 enzymes. Their breakdown products are amino acids rather than novel chemical metabolites. And their effects are shaped less by liver function and more by kidney function and albumin levels. None of this makes peptides inherently safer or more dangerous; it makes their pharmacokinetic behavior different, and understanding that difference is part of reading the class accurately.

Absorption, storage, and why handling affects the "dose"

One last practical thread ties pharmacokinetics back to the bench. Because a peptide is a fragile amino-acid chain, its effective dose depends on the molecule arriving intact, and that is a handling question as much as a pharmacokinetic one. Heat, foaming from rough reconstitution, and repeated freeze-thaw cycles can degrade a fraction of the peptide before it is ever administered, which quietly lowers the delivered dose and adds variability that can look like a pharmacokinetic effect. This is why research peptides ship lyophilized (freeze-dried) and are reconstituted gently, stored cold, and dated. The pharmacokinetics on paper only hold if the molecule in the vial matches the molecule that was studied.

The takeaway

Peptide pharmacokinetics reduces to one governing variable and a small set of engineering choices. The half-life sets the dosing interval, the time to steady state, and the washout; read it and most of a peptide's practical behavior follows. And the half-life itself is not a fixed property of the receptor the peptide hits; it is an engineered property, tuned by DPP-4 resistance, molecular size, acylation, and albumin binding. That is why compounds targeting the very same receptor can be dosed a minute apart or a week apart. For the retatrutide-specific pharmacokinetics, the reported ~6-day half-life and what it means for a research protocol, see how long retatrutide stays in your system.

For research and educational purposes only. Not medical advice. Reported pharmacokinetic figures describe published studies and are approximate ranges drawn from separate sources, not a dosing recommendation. The compounds referenced are research compounds and are not approved for human use.